Real-world Omni outcomes showed reductions in IOP and medication use in primary open-angle glaucoma or ocular hypertension. Outcomes were independent of cataract surgery. Stand-alone canaloplasty ...

Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

The OMNI Surgical System facilitates a minimally invasive glaucoma surgery (MIGS) procedure that does not require an implant and targets three areas of outflow resistance associated with glaucoma.

In a challenging market environment, Sight Sciences , Inc. (NASDAQ:SGHT) stock has touched a 52-week low, with shares falling to $2.54. With a market capitalization of $130.44 million and an ...

Jeremy B. Hayden, Chief Legal Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 6,922 shares of the company's common stock. The transactions occurred on January 17, 2025, at a weighted ...

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of ...

It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment ...

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.